Amgen Inc. (NASDAQ:AMGN) Declares Quarterly Dividend of $2.52

Amgen Inc. (NASDAQ:AMGN) announced a quarterly dividend on Tuesday, October 27th. Investors of record on Friday, November 20th will be paid a dividend of $2.52 per share by the medical research company on Friday, December 11th. This represents a $10.08 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Friday, November 20th.

Amgen has raised its dividend payment by an average of 0.1% annually over the last three years and has increased its dividend annually for the last 14 consecutive years. Amgen has a dividend payout ratio of 46.8% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Amgen to earn $24.61 per share next year, which means the company should continue to be able to cover its $10.08 annual dividend with an expected future payout ratio of 41.0%.

Amgen Trading Up 0.2%

Shares of AMGN opened at $448.92 on Wednesday. The business’s fifty day simple moving average is $418.42 and its two-hundred day simple moving average is $372.80. Amgen has a 12 month low of $288.00 and a 12 month high of $450.98.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating the consensus estimate of $5.62 by $0.67. The firm had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. During the same period in the previous year, the company earned $6.02 earnings per share. Amgen’s quarterly revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities analysts expect that Amgen will post 22.96 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on AMGN. Argus boosted their price objective on Amgen from $375.00 to $460.00 and gave the company a “buy” rating in a report on Wednesday, August 19th. Scotiabank raised their target price on shares of Amgen from $450.00 to $500.00 and gave the stock an “outperform” rating in a report on Monday, September 28th. Sanford C. Bernstein lifted their price objective on shares of Amgen from $335.00 to $345.00 and gave the company a “market perform” rating in a report on Thursday, August 6th. Cantor Fitzgerald increased their target price on Amgen from $400.00 to $440.00 and gave the company a “neutral” rating in a report on Monday, October 5th. Finally, Truist Financial raised their target price on Amgen from $362.00 to $380.00 and gave the stock a “hold” rating in a research note on Wednesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $389.71.

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.